Since replacing loss-of-function tumor suppressor mutations is challenging, drug therapeutic efforts have been directed towards identifying and understanding the effector pathways that mediate LKB1 tumor suppression in order to uncover new therapeutic strategies. Here, STK11 is linked to neoplasm.